CN114502585A - 通过抗体靶向吞噬作用除尽致病因子的方法 - Google Patents

通过抗体靶向吞噬作用除尽致病因子的方法 Download PDF

Info

Publication number
CN114502585A
CN114502585A CN202080038435.9A CN202080038435A CN114502585A CN 114502585 A CN114502585 A CN 114502585A CN 202080038435 A CN202080038435 A CN 202080038435A CN 114502585 A CN114502585 A CN 114502585A
Authority
CN
China
Prior art keywords
dectin
cells
antibody
phagocytosis
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080038435.9A
Other languages
English (en)
Chinese (zh)
Inventor
P·福塔基斯
C·M·陈
史若师
A·L·萨勒斯
N·托马塞维克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Durham Biology
Original Assignee
Durham Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durham Biology filed Critical Durham Biology
Publication of CN114502585A publication Critical patent/CN114502585A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202080038435.9A 2019-04-05 2020-04-03 通过抗体靶向吞噬作用除尽致病因子的方法 Pending CN114502585A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962830139P 2019-04-05 2019-04-05
US62/830,139 2019-04-05
PCT/US2020/026721 WO2020206354A1 (en) 2019-04-05 2020-04-03 Methods of depleting disease causing agents via antibody targeted phagocytosis

Publications (1)

Publication Number Publication Date
CN114502585A true CN114502585A (zh) 2022-05-13

Family

ID=72667025

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080038435.9A Pending CN114502585A (zh) 2019-04-05 2020-04-03 通过抗体靶向吞噬作用除尽致病因子的方法

Country Status (12)

Country Link
US (2) US20220169737A1 (enExample)
EP (1) EP3947467A4 (enExample)
JP (2) JP2022527646A (enExample)
KR (1) KR20220031995A (enExample)
CN (1) CN114502585A (enExample)
AU (1) AU2020253621A1 (enExample)
BR (1) BR112021019950A2 (enExample)
CA (1) CA3136272A1 (enExample)
IL (1) IL286967A (enExample)
MX (1) MX2021012035A (enExample)
SG (1) SG11202110663UA (enExample)
WO (1) WO2020206354A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102590454B1 (ko) 2016-07-07 2023-10-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
WO2021222894A1 (en) 2020-05-01 2021-11-04 Bolt Biotherapeutics, Inc. Anti-dectin-2 antibodies
MX2023004054A (es) 2020-10-07 2023-06-29 Dren Bio Inc Anticuerpos anti-dectina 1 y metodos de uso de los mismos.
CN119301156A (zh) * 2022-04-04 2025-01-10 德伦生物公司 抗Dectin-1抗体和其使用方法
US20250223364A1 (en) * 2022-04-04 2025-07-10 Dren Bio, Inc. Multispecific binding proteins that bind dectin-1 and cd20 and methods of use thereof
KR20260048578A (ko) * 2023-07-31 2026-04-10 드렌 바이오 매니지먼트, 인크. Dectin-1 및 TROP-2에 결합하는 다중특이적 결합 단백질 및 이의 사용 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679949B (zh) * 2007-02-23 2015-08-19 贝勒研究院 通过dectin-1激活人抗原呈递细胞的治疗性应用
WO2012129227A1 (en) * 2011-03-22 2012-09-27 Baylor Research Institute Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine
WO2018176159A1 (en) * 2017-03-31 2018-10-04 Zymeworks Inc. Tumor antigen presentation inducer constructs and uses thereof
US12384850B2 (en) * 2017-06-25 2025-08-12 Systimmune, Inc. Guidance and navigation control proteins and method of making and using thereof
CA3106796A1 (en) * 2018-07-19 2020-01-23 Oncohost Ltd Il-31 improves efficacy of macrophage-based adoptive cell therapy for cancer
EA202190183A1 (ru) * 2018-07-27 2021-05-18 Алектор Ллс Антитела к siglec-5 и способы их применения

Also Published As

Publication number Publication date
US20250206826A1 (en) 2025-06-26
BR112021019950A2 (pt) 2021-12-07
US20220169737A1 (en) 2022-06-02
SG11202110663UA (en) 2021-10-28
JP2022527646A (ja) 2022-06-02
MX2021012035A (es) 2022-03-11
AU2020253621A1 (en) 2021-11-11
CA3136272A1 (en) 2020-10-08
EP3947467A4 (en) 2023-01-04
KR20220031995A (ko) 2022-03-15
IL286967A (en) 2021-12-01
JP2025096316A (ja) 2025-06-26
WO2020206354A1 (en) 2020-10-08
EP3947467A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
US20250206826A1 (en) Methods of depleting disease causing agents via antibody targeted phagocytosis
JP7803942B2 (ja) 抗デクチン－１抗体及びその使用方法
US20200385471A1 (en) Bispecific antibodies against cd3epsilon and bcma for use in treatment of diseases
JP6975841B2 (ja) Ｃｄ１９に対するヒト化抗原結合ドメイン及び使用方法
US20110262461A1 (en) Biological materials and uses thereof
JP7299873B2 (ja) Ｃｄ３８抗体
JP2016523930A (ja) 骨髄異形成症候群（ｍｄｓ）を治療するための可溶性ｃｄ３３
JP7224338B2 (ja) Ｃｄ３８調節抗体
WO2021044039A1 (en) Ssea-4 binding members
KR20250006353A (ko) 항-덱틴-1 항체 및 이의 사용 방법
JP2025511389A (ja) デクチン－１及びｃｄ２０に結合する多重特異性結合タンパク質ならびにその使用方法
JP2022525937A (ja) Ｂｔｎ２に対する特異性を有する抗体及びその使用
Kim et al. Engineering bispecific T-cell engagers to deplete eosinophils for the treatment of severe eosinophilic asthma
EP4506368A1 (en) Bispecific antibody to human tim-3 and human cd39, and applications thereof
US20230192900A1 (en) Bispecific antibodies binding hvem and cd9
CN116724054A (zh) 抗Dectin-1抗体和其使用方法
HK40102072A (en) Bispecific antibodies against cd3epsilon and bcma for use in treatment of diseases
HK40101749A (zh) 抗dectin-1抗体和其使用方法
CN119487194A (zh) 融合蛋白
HK1244491B (en) Bispecific antibodies against cd3epsilon and bcma for use in treatment of diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: California, USA

Applicant after: Delun Biological Management Co.,Ltd.

Address before: California, USA

Applicant before: Durham biology

Country or region before: U.S.A.

CB02 Change of applicant information